90-Second Read: Hyundai Bioscience Positions XAFTY As Potential Ebola And Hantavirus Treatment Following Strong IC50 Findings

The IC50 level of XAFTY ® is even lower for the Ebola virus at 0.125 μM. Hyundai Bioscience reports that it has enough drug inventory for immediate supply to the outbreak frontlines. Antiviral Efficacy Against Hantavirus Expected XAFTY ® has reported on its broad antiviral activity. Efficacy against Ebola, More Than Double That Against COVID-19- Ready for Immediate Administration The IC50 data is the drug concentration that can inhibit viral replication by 50%.

This suggests that XAFTY ® could be a promising agent to treat Ebola-infected patients. It demonstrated exceptional inhibitory efficacy of less than 0.125 μM against the Severe Fever with Thrombocytopenia Syndrome (SFTS) virus, which serves as scientific evidence for activity against Hantavirus. Both SFTS virus and Hantavirus belong to the same virus class. No severe adverse events have been reported so far across all dosage groups, reaffirming its clinical safety.

Amid the current crisis of these two often fatal infectious diseases XAFTY ® should be considered for testing. The lower the value, the stronger the antiviral effect with a smaller amount. Safety Proven by COVID-19 Clinical Trials-Immediate Supply Available XAFTY ® proved its safety through the COVID-19 Phase 2/3 clinical trials and an ongoing Dengue Phase 2/3 clinical trial in Vietnam. Improving access to musculoskeletal care in the UK NCIS Leads Multidisciplinary Push To Transform Sarcoma Diagnosis And Care In Singapore From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem Lost your password?